FOLFOXIRI plus bevacizumab in the treatment of metastatic colorectal cancer patients with unresectable liver metastases

被引：0
|
作者：
Antoniotti, Carlotta [1 ,2 ]
Vetere, Guglielmo [1 ,2 ]
Cremolini, Chiara [1 ,2 ]
机构：
[1] Univ Hosp Pisa, Unit Med Oncol 2, Pisa, Italy
[2] Univ Pisa, Dept Translat Res & New Technol Med, Pisa, Italy
来源：
ANNALS OF TRANSLATIONAL MEDICINE | 2022年 / 10卷 / 18期
关键词：
1ST-LINE TREATMENT; OPEN-LABEL; FOLFIRI; PHASE-3; FLUOROURACIL; CHEMOTHERAPY; CAPECITABINE; OXALIPLATIN; LEUCOVORIN; IRINOTECAN;
D O I：
10.21037/atm-22-3656
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [1] Impact of FOLFOXIRI plus bevacizumab on resectability and survival in patients with initially unresectable liver metastases from colorectal cancer.
    Shimada, M.
    Nishioka, M.
    Hanaoka, J.
    Mori, H.
    Ikemoto, T.
    Imura, S.
    Morine, Y.
    Utsunomiya, T.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [2] FOLFOXIRI plus Bevacizumab in metastatic colorectal Cancer
    不详
    [J]. ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2020, 58 (07): : 630 - 630
  • [3] HISTOPATHOLOGICAL RESPONSE TO FOLFOXIRI PLUS BEVACIZUMAB OF LIVER METASTASES FROM COLORECTAL CANCER
    Caparello, Chiara
    Loupakis, Fotios
    Schirripa, Marta
    Funel, Niccola
    Pollina, Luca
    Vasile, Enrico
    Cremolini, Chiara
    Salvatore, Lisa
    Masi, Gianluca
    Fornaro, Lorenzo
    Campani, Daniela
    Falcone, Alfredo
    [J]. ANNALS OF ONCOLOGY, 2011, 22 : v95 - v95
  • [4] Histopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab
    F Loupakis
    M Schirripa
    C Caparello
    N Funel
    L Pollina
    E Vasile
    C Cremolini
    L Salvatore
    M Morvillo
    C Antoniotti
    F Marmorino
    G Masi
    A Falcone
    [J]. British Journal of Cancer, 2013, 108 : 2549 - 2556
  • [5] Histopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab
    Loupakis, F.
    Schirripa, M.
    Caparello, C.
    Funel, N.
    Pollina, L.
    Vasile, E.
    Cremolini, C.
    Salvatore, L.
    Morvillo, M.
    Antoniotti, C.
    Marmorino, F.
    Masi, G.
    Falcone, A.
    [J]. BRITISH JOURNAL OF CANCER, 2013, 108 (12) : 2549 - 2556
  • [6] FOLFOXIRI plus bevacizumab (bev) as upfront treatment for metastatic colorectal cancer (mCRC) patients (pts) with initially unresectable liver-limited disease (LLD)
    Casagrande, M.
    Cremolini, C.
    Zucchelli, G.
    Bergamo, F.
    Ferrari, L.
    Pietrantonio, F.
    Lonardi, S.
    Loupakis, F.
    Masi, G.
    Pella, N.
    Intini, R.
    Salvatore, L.
    Tomasello, G.
    Pagani, F.
    Pellino, A.
    Dell'Aquila, E.
    Ginocchi, L.
    Milione, M.
    Fea, E.
    Pellegrinelli, A.
    Falcone, A.
    [J]. ANNALS OF ONCOLOGY, 2016, 27
  • [7] Efficacy of FOLFOXIRI versus XELOXIRI plus bevacizumab in the treatment of metastatic colorectal cancer
    Cheng, Yuzhuo
    Song, Weiliang
    [J]. INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2015, 8 (10): : 18713 - 18720
  • [8] Comment on 'Histopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab'
    Bibeau, F.
    Gil, H.
    Castan, F.
    Boissiere-Michot, F.
    [J]. BRITISH JOURNAL OF CANCER, 2013, 109 (12) : 3127 - 3129
  • [9] Comment on ‘Histopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab’
    F Bibeau
    H Gil
    F Castan
    F Boissière-Michot
    [J]. British Journal of Cancer, 2013, 109 : 3127 - 3129
  • [10] FOLFOXIRI plus bevacizumab as conversion-therapy for liver metastases in colorectal cancer: A necessity?
    Modest, D. P.
    Neumann, U. P.
    Pratschke, J.
    [J]. EUROPEAN JOURNAL OF CANCER, 2017, 73 : 71 - 73
12345